Puma Biotechnology presents positive PB272 clinical data at ASCO

RELATED QUOTES

SymbolPriceChange
PBYI37.53

Puma Biotechnology announced that results from an ongoing Phase I clinical trial of its lead drug candidate PB272 (neratinib) given in combination with the anticancer drugs paclitaxel and trastuzumab in patients with metastatic HER-2 positive breast cancer were presented in a poster presentation at the American Society of Clinical Oncology, ASCO, 2012 Annual Meeting. This trial was sponsored by the National Surgical Adjuvant Breast and Bowel Project, NSABP, a clinical trials cooperative group supported by the National Cancer Institute,NCI.

  •  
    Recent Quotes
    Symbol Price Change % ChgChart 
    Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
    You need to enable your browser cookies to view your most recent quotes.
  • Recent Quotes News

    •  
      Sign-in to view quotes in your portfolios.

    Trading Center

    Yahoo! Finance on Facebook

    POLL

    Do you trust the IRS in light of its recent scandals?

    Loading...
    Poll Choice Options